TOP ƒJƒeˆê—— ƒXƒŒˆê—— 100`I‚Ü‚Å 2chŒ³ 휈˗Š
y‘åãz‚±‚ê‚Å‚¢‚¢‚Ì‚©H»–ò‹ÆŠE
yMPz“®•¨—pˆã–ò•i‹ÆŠE 23 yŠ¢Žzz
yƒLƒ€Eƒeƒq zƒ[ƒg»–ò•s”ƒ‰^“®yCM–â‘èz
V¶ƒJƒvƒXƒQƒ‹
—Õ°HŠw‹ZŽm‚Á‚Ä‚Ç‚¤‚æ
•“c–ò•i@‘‡ƒXƒŒƒbƒh39 ƒVƒƒƒPƒ_”½UŠJŽn
ƒZƒ‹ƒW[ƒ“ part2
yŠw—ðzŠÅŒìŽtpart1yƒ‰ƒ“ƒLƒ“ƒOz
‰·ò‚Ó‚Ÿ[‚Ü”U‘ÊŽR‰«“ꎖŒ
yƒpƒƒnƒ‰z“®•¨—pˆã–ò•i‹ÆŠE@19 yƒZƒNƒnƒ‰z
- 434 F
- •Ä‘CMS‚ÌOPENƒf[ƒ^‚æ‚èB
Doctors and teaching hospitals received $8.4 billion from drug and device companies in 2017,
according to the latest Centers for Medicare and Medicaid Services Open Payments data.
Open Payments published 11.54 million payment records.
Payments included nearly $4.7 billion in research-related payments, $2.82 billion in non-research-related payments,
such as meals, fees and travel to speaking events and more than $927 million in ownership or investment interests held by physicians or immediate family members.
About 628,000 doctors received $79.1 million in research-related payments.
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program \ $560 million.
Royalty of license \ $499 million
Consulting fee \ $409 million
Food and beverage \ $237 million
Travel and lodging \ $188 million
https://openpaymentsdata.cms.gov/summary
“¿“cŒÕ—YH
yCAz@“®•¨—pˆã–ò•i‹ÆŠE@21 @yLSz
ˆã—ËƊE‚Á‚ă„ƒNƒU‚Á‚Ä‚¢‚é‚ÌH
ƒTƒmƒtƒB‚Á‚Ä‚Ç‚¤‚Å‚·‚©HPart3
ƒoƒCƒIƒVƒ~ƒ‰[Õ‚è
ˆã—Ë@Ší‚̉c‹Æƒ}ƒ“W‚Ü‚ê part12
ƒRƒ“ƒgƒ‰ƒNƒg‚l‚q‚̔߈£
•ÛŒ’‰ÈŠwŒ¤‹†Šy4z
y“DMzƒNƒCƒ“ƒ^ƒCƒ‹ƒYMR‚̺y’¾–v‘Ò‚Á‚½–³‚µz
ƒŒ[ƒVƒbƒN‚É‚æ‚é—Γàá‚̊댯‚à
--------------------
V‚µ‚’ʉݔs‚µ‚½‚ñ‚¾‚ª’N‚©•‚¯‚Ä‚‚ê‚È‚¢‚©
y‚±‚±z‘½–€ŒÎƒTƒCƒNƒŠƒ“ƒOƒh[ƒ22“¹–Úy‰º—¬z
yMH3GzƒLƒƒƒ‰ƒNƒ^[ƒƒCƒLƒ“ƒO‘‡ƒXƒŒy3DSz
ŒÇ“Æ‚È’j‚½‚¿‚Ì”N––”NŽnƒXƒŒ@‚Q“ú–Ú
yPSO2zŒÀ’胊ƒTƒCƒNƒ‹ƒVƒ‡ƒbƒvA–³‚µI
stRenault Kangoo/ƒ‹ƒm[ƒJƒ“ƒO[ Part47st
ƒAƒjƒƒCƒgƒQ[ƒ}[ƒY‚Ńiƒ“ƒp‚h‚ŽŠÖ¼
L“‡l(L“‡•Ù‚ðŽg‚¤l)‚Í‚È‚º’á”]‚È‚Ì‚©
y”ªŒËz“Œ–kƒtƒŠ[ƒuƒŒƒCƒY7yŒSŽRz
y‚«‚ñ‚É‚z ƒXƒ}ƒCƒ‹EƒXƒ^ƒCƒ‹ ‹Ø“÷™‘¾˜Y 1muscle y‚Ü‚Á‚·‚éz
yƒIƒŠƒbƒNƒXzBsGirls31@yƒoƒtƒ@ƒ[ƒYz
y•²–¡zVŠƒ‰w‘OƒXƒ|[ƒcƒNƒ‰ƒuy”kAƒnƒQAƒ’ƒ^z
5Žü”N‚ðŒ}‚¦‚½‰ÄŠC‚̃XƒŒ‚Å
‚â‚ç‚©‚µ’à2y–³—¿Ä¯Ëßݸ޷‚è•ú‘èz
y’†“Œî¨‚Ö‚ÌŒ¾‹y–³‚µz#ˆÀ”{Žñ‘Š A‹x‰É’†‚É‚S‰ñ‚àƒSƒ‹ƒt@”N––”NŽnu‚ä‚Á‚‚肵‚½v
y¡‘å‰ïˆê‚̋Ɉ«ƒq[ƒ‹‚ZzŽ ‰ê.‘VŠy•‰‚¯‚ðŒ©“Í‚¯‚éƒXƒŒz
ŽO‘Žu‘åí‚S‚ÉŠú‘Ò‚·‚邱‚Æ
ƒgƒ‰ƒ“ƒyƒbƒg‰¹ŠO‚µ™ƒƒƒ^
èI‹„Žt‚Ì‹xŒeŽº
ƒ[ƒmƒuƒŒƒCƒh2‚‚܂ç‚ñ
TOP ƒJƒeˆê—— ƒXƒŒˆê—— 100`I‚Ü‚Å 2chŒ³ 휈˗Š